Abiopharma

🔍 STEVENS ROBERT J (Executive)

Company: PRICE T ROWE GROUP INC (TROW)

Report Date: 2026-06-29

Detailed Transactions and Holdings:

• Acquired 278 shares of Common Stock at $114.38 per share (Direct)
  Date: 2026-06-29 | Code: A | equity_swap_involved: false | shares_owned_after: 24,709.35 | transaction_form_type: 4 | Footnotes: F1
• Acquired 537 shares of Common Stock (Direct)
  Date: 2026-06-30 | Code: A | equity_swap_involved: false | shares_owned_after: 25,246.35 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: This is pursuant to the T. Rowe Price Group, Inc. 2017 Non-Employee Director Equity Plan with respect to dividends declared by the issuer on it's Common Stock. A portion of these shares were credited as fully-vested dividend reinvestment shares and a portion will be accrued and vest when the corresponding grant vests.
• F2: Pursuant to the 2017 Non-Employee Director Equity Plan, Stock Units were issued for Director Fee Awards at $113.69 per share, the closing price of TROW shares on June 30, 2026. The Stock Unit Shares and any future dividends attributed to such Director Fee Award, will vest in full and become nonforfeitable on the date of grant.